Dr. John Lebbos, M.D., therapeutic area director at Decision Resources, is available to discuss the impact of the U.S. Food and Drug Administration's (FDA) approval of Merck's Gardasil, the first vaccine for cervical cancer.
Studies show virtually all cases of cervical cancer are caused by a virus known as human papillomavirus, or HPV. It is transmitted sexually and most of the time human immune systems can get rid of it, but in about 10,000 women a year it develops into cervical cancer.
Gardasil is expected to be available late this summer, according to Merck. Dr. Lebbos can provide: * Insight on the commercial potential of the vaccine and forecast of the HPV vaccine market. * Key factors that will have an impact on its uptake and use. What will be the main drivers and barriers for its use? * Potential health and economic benefits of HPV vaccination.
Dr. John Lebbos, M.D., is therapeutic area director of infectious disease at Decision Resources, Inc. He has had extensive experience in product valuation and sales forecasting in the antibacterial, antiviral, antifungal, and vaccine markets.
To talk with Dr. Lebbos, please contact Liz Marshall at 781-296-2563 or firstname.lastname@example.org.
About Decision Resources
Decision Resources, Inc. (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall 781-296-2563 email@example.com
PRNewswire -- June 9
SOURCE: Decision Resources, Inc.
Web site: http://www.decisionresources.com/